PK and Safety of Rupatadine in Hepatic Impairment

Phase 1, open-label trial of rupatadine in allergic rhinitis (AR) and urticaria (4 arms), sponsored by Noucor Health S.A. Primary endpoints: Area under the plasma concentration-time curve from time zero to last time point at 10 days, Area under the plasma concentration-time curve from time zero to infinity at 10 days and 10 more. Started Nov 2022; status: completed.